Protagonist Therapeutics, Inc. (PTGX)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 4.7M | 7.4M | 56.4M | 213.5M |
| Operating Income | (46.4M) | (50.4M) | (3.6M) | 158.8M |
| Net Income | (39.3M) | (44.4M) | 3.8M | 162.8M |
| Diluted EPS | $-0.62 | $-0.69 | $0.05 | $2.29 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 26.6M | 60.0M | 434.4M | 46.0M |
| Operating Income | (131.4M) | (93.7M) | 252.8M | (158.1M) |
| Net Income | (127.4M) | (79.0M) | 275.2M | (130.1M) |
| Diluted EPS | $-2.60 | $-1.39 | $4.23 | $-2.05 |